# March Biosciences

Source: https://onco.cc/companies/march-biosciences/  
OnCo record `march-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

March Biosciences makes a CAR-T cell therapy aimed at the protein CD5 to treat T-cell lymphomas, blood cancers for which few targeted treatments exist.

## Summary

March Biosciences Inc., based in Houston, Texas and co-founded by Sarah Hein, Maksim Mamonkin and Malcolm Brenner, develops CAR T cell therapies for haematological cancers, using an approach it says unlocks targets without additional gene editing. MB-105 is a CD5-directed CAR T cell therapy in a phase 2 trial in CD5-positive T-cell lymphoma (NCT06534060). Its first registered cancer trial, NCT06534060, was posted on ClinicalTrials.gov in August 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: march.biosciences; March Biosciences Inc
- HQ: Houston, TX
- Type: cell-therapy
- Website: https://march.bio/

## Notes

- Company website read on 29 October 2026. Founding year not stated. No financing round was read. OnCo has no CD5 target record, so no target relation is made.

## Sources

- Official website: https://march.bio/
- About and team: https://march.bio/about/

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- trials: [MB-105 in Patients With CD5 Positive T-cell Lymphoma](https://onco.cc/trials/nct06534060/)

---
JSON: https://onco.cc/api/v1/entities/march-biosciences.json